Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis

Leukemia. 2004 May;18(5):1027-9. doi: 10.1038/sj.leu.2403329.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Benzamides
  • Bone Marrow Cells / immunology
  • Bone Marrow Cells / pathology
  • Eosinophilia / complications*
  • Eosinophilia / immunology
  • Eosinophilia / pathology
  • Humans
  • Imatinib Mesylate
  • Immunophenotyping
  • Male
  • Mast Cells / immunology*
  • Mast Cells / pathology
  • Mastocytosis, Systemic / drug therapy*
  • Mastocytosis, Systemic / immunology
  • Mastocytosis, Systemic / pathology
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate